Medpace (MEDP) Sets New 12-Month High and Low at $43.01

Medpace Holdings (NASDAQ:MEDP)’s share price hit a new 52-week high and low during mid-day trading on Friday . The stock traded as low as $43.01 and last traded at $43.04, with a volume of 9412 shares changing hands. The stock had previously closed at $41.75.

Several equities analysts recently issued reports on MEDP shares. ValuEngine upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Credit Suisse Group restated an “outperform” rating and set a $42.00 price target (up from $41.00) on shares of Medpace in a research note on Tuesday, February 27th. Jefferies Group restated a “hold” rating and set a $35.00 price target on shares of Medpace in a research note on Thursday, March 1st. Mitsubishi UFJ Financial Group restated a “neutral” rating and set a $40.00 price target on shares of Medpace in a research note on Friday, April 20th. Finally, Robert W. Baird set a $35.00 price target on Medpace and gave the company a “hold” rating in a research note on Tuesday, April 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $37.83.

The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.41. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of 28.04, a P/E/G ratio of 1.59 and a beta of 0.07.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, April 30th. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.17. The company had revenue of $108.40 million for the quarter, compared to the consensus estimate of $113.12 million. Medpace had a return on equity of 12.50% and a net margin of 10.37%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.34 earnings per share. equities research analysts predict that Medpace Holdings will post 1.92 EPS for the current fiscal year.

In other Medpace news, major shareholder Medpace Limited Partnership sold 3,000,000 shares of Medpace stock in a transaction that occurred on Monday, May 7th. The stock was sold at an average price of $35.49, for a total transaction of $106,470,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 29.50% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Koch Industries Inc. acquired a new stake in Medpace during the fourth quarter valued at approximately $279,000. Quadrature Capital Ltd acquired a new position in shares of Medpace in the 4th quarter worth approximately $443,000. Goldman Sachs Group Inc. boosted its holdings in shares of Medpace by 8.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 48,380 shares of the company’s stock worth $1,754,000 after acquiring an additional 3,761 shares in the last quarter. Allianz Asset Management GmbH acquired a new position in shares of Medpace in the 4th quarter worth approximately $765,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Medpace in the 4th quarter worth approximately $7,252,000. 25.48% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply